Maulida - Mazaya

Dr. Maulida - Mazaya

National Research and Innovation Agency (BRIN, Badan Riset dan Inovasi Nasional), Republic of Indonesia, Bogor, Jawa Barat, Indonesia
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Biotechnology Notes
Verified
Journal Article
Open access
ISImmanuel Sanka
Immanuel Sanka
AKAli Budhi Kusuma
Ali Budhi Kusuma
FMFaustina Martha
Faustina Martha
AHAndre Hendrawan
Andre Hendrawan
IPIhsan Tria Pramanda
Ihsan Tria Pramanda
AWAulia Reski Widyaningrum
Aulia Reski Widyaningrum
Synthetic biology has gained many interest around the globe in the last two decades, not only due to its rapid development but also the potential to provide addressable solutions using standardized design of biological systems. Considering its huge population, biodiversity, and natural resources, Indonesia could play an important role in shaping the future of synthetic biology towards a sustainable bio-circular economy. Here, we provide an overview of synthetic biology development in Indonesia, especially on exploring the potential of our biodiversity. We also discuss some potentials of synthetic biology in solving national issues. Furthermore, we also provide the projection and future landscape of synthetic biology development in Indonesia. In addition, we briefly explain the potential challenges that may arise during the development.

4 May 2024 in World Journal of Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
KNKhurul Aini Indah Nurjannah
Khurul Aini Indah Nurjannah
AMApon Zaenal Mustopa
Apon Zaenal Mustopa
AMAndi Masniawati
Andi Masniawati
FFFatimah Fatimah
Fatimah Fatimah
HIHerman Irawan
Herman Irawan
ZBZubaidi Bachtiar
Zubaidi Bachtiar

18 August 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
MMMaulida - Mazaya
Maulida - Mazaya
YKYung-Keun Kwon
Yung-Keun Kwon
Pleiotropy, which refers to the ability of different mutations on the same gene to cause different pathological effects in human genetic diseases, is important in understanding system-level biological diseases. Although some biological experiments have been proposed, still little is known about pleiotropy on gene–gene dynamics, since most previous studies have been based on correlation analysis. Therefore, a new perspective is needed to investigate pleiotropy in terms of gene–gene dynamical characteristics. To quantify pleiotropy in terms of network dynamics, we propose a measure called in silico Pleiotropic Scores (sPS), which represents how much a gene is affected against a pair of different types of mutations on a Boolean network model. We found that our model can identify more candidate pleiotropic genes that are not known to be pleiotropic than the experimental database. In addition, we found that many types of functionally important genes tend to have higher sPS values than other genes; in other words, they are more pleiotropic. We investigated the relations of sPS with the structural properties in the signaling network and found that there are highly positive relations to degree, feedback loops, and centrality measures. This implies that the structural characteristics are principles to identify new pleiotropic genes. Finally, we found some biological evidence showing that sPS analysis is relevant to the real pleiotropic data and can be considered a novel candidate for pleiotropic gene research. Taken together, our results can be used to understand the dynamics pleiotropic characteristics in complex biological systems in terms of gene–phenotype relations.

25 January 2025 in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Verified
Journal Article
Closed access
DHDini Hayati
Dini Hayati
MMMaulida - Mazaya
Maulida - Mazaya
SHSeung-Hoon Han
Seung-Hoon Han
JHJongin Hong
Jongin Hong

31 December 2023 in Genomics & Informatics
Verified
Journal Article
Open access
PDF file
MMMuhammad Ma’rUf
Muhammad Ma’rUf
Lalu Muhammad IrhamLalu Muhammad Irham
Lalu Muhammad Irham
Wirawan AdikusumaWirawan Adikusuma
Wirawan Adikusuma
MSMade Ary Sarasmita
Made Ary Sarasmita
SKSabiah Khairi
Sabiah Khairi
LSLalu Muhammad Harmain Siswanto
Lalu Muhammad Harmain Siswanto
Liver cancer is the fourth leading cause of death worldwide. Well-known risk factors include hepatitis B virus and hepatitis C virus, along with exposure to aflatoxins, excessive alcohol consumption, obesity, and type 2 diabetes. Genomic variants play a crucial role in mediating the associations between these risk factors and liver cancer. However, the specific variants involved in this process remain under-explored. This study utilized a bioinformatics approach to identify genetic variants associated with liver cancer from various continents. Single-nucleotide polymorphisms associated with liver cancer were retrieved from the genome-wide association studies catalog. Prioritization was then performed using functional annotation with HaploReg v4.1 and the Ensembl database. The prevalence and allele frequencies of each variant were evaluated using Pearson correlation coefficients. Two variants, rs2294915 and rs2896019, encoded by the PNPLA3 gene, were found to be highly expressed in the liver tissue, as well as in the skin, cell-cultured fibroblasts, and adipose-subcutaneous tissue, all of which contribute to the risk of liver cancer. We further found that these two SNPs (rs2294915 and rs2896019) were positively correlated with the prevalence rate. Positive associations with the prevalence rate were more frequent in East Asian and African populations. We highlight the utility of this population-specific PNPLA3 genetic variant for genetic association studies and for the early prognosis and treatment of liver cancer. This study highlights the potential of integrating genomic databases with bioinformatic analysis to identify genetic variations involved in the pathogenesis of liver cancer. The genetic variants investigated in this study are likely to predispose to liver cancer and could affect its progression and aggressiveness. We recommend future research prioritizing the validation of these variations in clinical settings.

1 January 2025 in SCRIPTA MEDICA
Verified
Journal Article
Open access
PDF file
PBPrasetya Henry Budiawan
Prasetya Henry Budiawan
APAmukti Danang Prasetyaning
Amukti Danang Prasetyaning
Lalu Muhammad IrhamLalu Muhammad Irham
Lalu Muhammad Irham
Wirawan AdikusumaWirawan Adikusuma
Wirawan Adikusuma
MMMaulida - Mazaya
Maulida - Mazaya
DRDaraporn Rungprai
Daraporn Rungprai
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are dermatological emergencies characterised by widespread epidermal necrolysis and sloughing. SJS is defined as the shedding of skin on less than 10 % of the body surface area, whereas TEN involves the shedding of skin on more than 30 %. The pathogenesis of SJS is identified by the occurrence of apoptosis of keratinocytes, which is spread throughout the body. The binding of the molecule to the human leukocyte antigen (HLA) peptide is one of the basic triggering mechanisms for SJS due to an autoimmune reaction. This study aims to predict genetic predictive markers for the prevention and pharmacological treatments of SJS/TEN. The PharmGKB website was used to gather information regarding the relationship among drugs, genes and the SJS condition. Results revealed notable gene variants (eg HLA-A, HLA-B, HLA-B, HLA-C, CYP2B6) predisposing individuals to a toxic response, instigating the SJS reaction. Implicated drugs included allopurinol, antiepileptics such as carbamazepine, lamotrigine, oxcarbazepine and phenytoin, as well as methazolamide and nevirapine, identified as potential risk factors. As a result, this study can provide information and facilitate precision medicine, which focuses on individual genetic variations as a means of prevention and treatment, enabling early prognosis and optimising patient care in preventing SJS/TEN.